Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00955305 · ClinicalTrials.gov registry record · Phase 2
Paclitaxel, Carboplatin, and Bevacizumab With or Without Cixutumumab in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- Phase 2
- Development phase
- 175
- Enrollment target
NCT00955305: Clinical Trial Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00955305 is a Phase 2 study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 175 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00955305, a Phase 2 study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 175 participants
- Enrollment target
Study Summary
This randomized phase II trial studies how well carboplatin, paclitaxel, and bevacizumab (CPB) work when given with or without cixutumumab in treating patients with non-small cell lung cancer that is stage IV or has come back (recurrent). Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as bevacizumab, may interfere with the ability of tumor cells to grow and spread. Other types of monoclonal antibodies, such as cixutumumab, may find tumor cells and help kill them. It is not yet known whether giving more than one drug (combination chemotherapy) together with bevacizumab is more effective when given with or without cixutumumab in treating patients with non-small cell lung cancer.
Interventions
- DRUG Carboplatin
- DRUG Paclitaxel
- BIOLOGICAL Bevacizumab
- BIOLOGICAL Cixutumumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 175 participants |
| Start Date | 2010-03 |
| Est. Completion | 2016-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00955305
The ClinicalTrials.gov registry entry for NCT00955305 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 175 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Carboplatin is the first listed.
NCT00955305 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00955305 about?
NCT00955305 is a clinical study titled "Paclitaxel, Carboplatin, and Bevacizumab With or Without Cixutumumab in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer". This randomized phase II trial studies how well carboplatin, paclitaxel, and bevacizumab (CPB) work when given with or without cixutumumab in treating patients with non-small cell lung cancer that is stage IV or has come back (recurrent). Drugs used in chemotherapy, such as paclitaxel and carboplati...
What is the current status of trial NCT00955305?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 175 participants. The study started on 2010-03. Estimated completion is 2016-11.
What interventions are being tested in trial NCT00955305?
The interventions under investigation include: Carboplatin (DRUG), Paclitaxel (DRUG), Bevacizumab (BIOLOGICAL), Cixutumumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00955305?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.